Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
Healthcare
$9.52 +0.14%
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
52W Low $7.95High $28.25
Volume 9.96M
Average 6.11M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$348.88M
FY 2025 · Annual
Investing Cash Flow
$125.57M
FY 2025 · Annual
+0.0% YoYFinancing Cash Flow
$185.75M
FY 2025 · Annual
+0.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (519.02M) |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M |
| Deferred Income Tax | 8.93M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M |
| Change in Working Capital | (22.9M) | (53.87M) | (52.45M) | 11.88M | (73.75M) |
| Accounts Receivables | 99K | (1.74M) | (32.69M) | 27.94M | (951K) |
| Inventory | 7.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | 529K | (4.58M) | 2.52M | 6.8M | 5.99M |
| Other Working Capital | (31.36M) | (47.55M) | (22.29M) | (22.86M) | (78.79M) |
| Other Non-Cash Items | 2.94M | 95.8M | (3.47M) | (6.3M) | 79.34M |
| Operating Cash Flow | (225.03M) | (333.29M) | (394.09M) | (348.88M) | (348.88M) |
| Capital Expenditures | (12.76M) | (58.39M) | (13.99M) | (5.78M) | (5.78M) |
| Acquisitions (Net) | (3M) | (44.68M) | 0 | 0 | 0 |
| Purchases of Investments | (1.02B) | (429.03M) | (904.46M) | (935.57M) | (935.57M) |
| Sales of Investments | 485.6M | 647.58M | 887.1M | 1.07B | 1.05B |
| Other Investing Activities | 0 | 44.83M | 0 | 0 | 20.97M |
| Investing Cash Flow | (550.78M) | 160.31M | (31.35M) | 125.57M | 125.57M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 693.57M | 565.79M | 119.8M | 176.9M | 131.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.12M | 17.17M | 10.53M | 8.85M | 54.26M |
| Financing Cash Flow | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (39.12M) | 409.98M | (295.11M) | (37.57M) | (37.57M) |
| Free Cash Flow | (237.79M) | (391.68M) | (408.07M) | (354.66M) | (354.66M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$519.0M
+ D&A$10.3M
+ Stock-Based Comp$154.3M
+ Deferred Tax$0
- Working Capital-$73.8M
+ Other Non-Cash$79.3M
= Operating Cash Flow-$348.9M
- Capex-$5.8M
= Free Cash Flow-$354.7M
Analysis
FY2025 free cash flow is -$354.7M. FCF conversion is 68.3% of net income. Operating cash flow was -$348.9M, with capex of -$5.8M. The largest bridge item is Stock-Based Comp at $154.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K/A | 8-K/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does NTLA generate free cash flow?
Intellia Therapeutics, Inc. (NTLA) generated -$354.66M of free cash flow in fiscal 2025.
How much operating cash flow does NTLA produce?
Operating cash flow was -$348.88M, before capital expenditures of $5.78M.
Continue the stock analysis
Jump to another research area for this company.